Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
VS-505
DIETARY_SUPPLEMENT
2 trials
Sponsors
KDL Inc.
, Shanghai Alebund Pharmaceuticals Limited
Conditions
End Stage Renal Disease
Hyperphosphatemia
Phase 1
A Dose Escalation Study of VS-505 in End Stage Renal Disease Patients Undergoing Hemodialysis
NCT02469467
KDL Inc.
End Stage Renal Disease, Hyperphosphatemia
Start: 2015-06-30
End: 2016-12-31
Target: 30
Updated: 2016-02-08
Phase 2
A Phase 2 Study to Evaluate the Safety and Efficacy of VS-505(AP301) to Treat Hyperphosphatemia in Hemodialysis Patients
Completed
NCT04551300
Shanghai Alebund Pharmaceuticals Limited
Hyperphosphatemia
Start: 2020-10-13
End: 2022-10-15
Updated: 2022-10-18
Related Papers
Tolerability, safety and efficacy of a novel phosphate binder VS-505 (AP301): a Phase 2 dose-escalation and dose-ranging study in patients undergoing maintenance hemodialysis
Nephrology Dialysis Transplantation
2024-03-07
2 citations